Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,698.79
(
-0.26%
)
US TECH 100
24,048.00
(
-0.35%
)
Dow Jones
46,814.19
(
-0.38%
)
Brent Oil
105.38
(
4.69%
)
Bitcoin
72,498.44
(
-1.95%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rkrw post# 65973

Tuesday, 09/09/2008 4:02:15 PM

Tuesday, September 09, 2008 4:02:15 PM

Post# of 257253
>BIOD – There actually is a lot of interest in the diabetes community for this…<

I guess I don’t see the attraction from a business standpoint of an enhanced formulation of a product—ordinary insulin—that is in a state of steady and irreversible decline.

What is the allure of BIOD’s reformulation (and similar products from other companies) versus an insulin analog or cocktail of analogs? T.i.a.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now